Navigation Links
Sangamo BioSciences Announces Research Collaboration With UCLA in Human Stem Cells Selected to Receive Clinical Research Award
Date:10/1/2009

RICHMOND, Calif., Oct. 1 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that research led by Donald B. Kohn, M.D., Professor of Microbiology, Immunology and Molecular Genetics (MIMG) and Pediatrics, the Director of the UCLA Human Gene Medicine Program and member of the Broad Stem Cell Research Center, and Philip Gregory, D. Phil., Sangamo's chief scientific officer and vice president, research, has been selected to receive a $486,000 Doris Duke Innovations in Clinical Research Award from the Doris Duke Charitable Foundation. The grant, which will be paid over three years, will support an innovative research project conducted by Dr. Kohn and Sangamo scientists and titled "Beta-globin Gene Correction in Hematopoietic Stem Cells for Sickle Cell Disease."

"ZFN-mediated gene editing is an exciting and now proven technology with the potential to provide a solution for sickle cell anemia and other hemoglobinopathies," said Dr. Kohn. "Despite the fact that sickle-cell anemia was the first genetic disorder for which a molecular cause was identified and one in which every patient has the same gene mutation, the lack of treatment options makes the disease a hugely important problem worldwide. This novel approach will develop the use of efficient ZFN-mediated correction of the sickle mutation in the human beta-globin gene in stem cells from patients with sickle cell disease rather than traditional approaches of gene replacement therapy."

The Doris Duke Innovations in Clinical Research Award (ICRA) provides seed funding for early stage, multi-disciplinary clinical research projects. The 2009 ICRA grants will support a range of approaches to improving the health of patients with sickle cell disease. The research proposed by Dr. Kohn and Sangamo is one of five projects selected to receive grants from t
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
2. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
3. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
4. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
5. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
6. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
7. Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
8. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells
9. Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
10. Sangamo BioSciences Provides Update on Companys 2008 Progress and 2009 Objectives
11. Sangamo BioSciences Announces Presentations at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , July 24, 2014  IRIDEX Corporation (NASDAQ: ... its second quarter 2014 financial results after the market ... conjunction with the release, the Company will host a ... p.m. Eastern Time on Thursday, July 31, ... and other business developments. Interested parties may ...
(Date:7/24/2014)... and MENLO PARK, Calif. , July ... DMPI) ("DelMar" "the company") announced today that the company,s board ... from December 31 to June 30. Accordingly, DelMar will file ... Jeffrey Bacha , president and CEO of ... important step in achieving our goal of obtaining a senior ...
(Date:7/24/2014)... 2014  Kinex Pharmaceuticals announced the receipt of an ... Ointment for the commencement of a Phase I clinical ... IND to be allowed by the US FDA in ... synthetic, orally active and highly selective inhibitor of Src ... induction of p53, G2/M arrest of proliferating cell populations ...
Breaking Medicine Technology:DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 2DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 3Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 2Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 3Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 4
... , , NEW YORK , Feb. 9 ... online, print and print-on-demand publication from LIVE STRONG .  The magazine ... resources and information about cancer prevention and treatment; and general articles ... survivor, I understand the worries and concerns other survivors face on ...
... SAN DIEGO , Feb. 9 Volcano Corporation ... precision intravascular therapy guidance tools designed to enhance the diagnosis ... that it has received 510(k) clearance from the U.S. Food ... digital IVUS catheter in the United States . This ...
Cached Medicine Technology:SPOT ON media and LIVESTRONG(R) Launch LIVESTRONG Quarterly 2SPOT ON media and LIVESTRONG(R) Launch LIVESTRONG Quarterly 3SPOT ON media and LIVESTRONG(R) Launch LIVESTRONG Quarterly 4Volcano Receives FDA Clearance to Market the Eagle Eye(R) Platinum Digital IVUS Catheter 2Volcano Receives FDA Clearance to Market the Eagle Eye(R) Platinum Digital IVUS Catheter 3Volcano Receives FDA Clearance to Market the Eagle Eye(R) Platinum Digital IVUS Catheter 4
(Date:7/24/2014)... (PRWEB) July 24, 2014 The ... http://www.injurybeacon.com/granuflo-dialysis/lawsuit/ ) in the U.S. District Court, ... order for plaintiff medical information covered by the ... to the July 16th Order, U.S. District Judge ... for Fresenius Medical Care the right to receive ...
(Date:7/24/2014)... July 24, 2014 CarePoint Health ... in hematology and oncology, Dr. Hitendra Upadhyaya, has ... system welcomes Dr. Upadhyaya to the community. Hundreds ... Health Medical Group, a comprehensive network of top ... wide range of specialties. This latest acquisition represents ...
(Date:7/24/2014)... N.Y. Primary care treatment of overweight and obese ... child compared to when only the child is targeted, ... and conducted at the University at Buffalo and ... this study were overweight or obese and had one ... overweight or obese, according to body mass index (BMI) ...
(Date:7/24/2014)... more equally positive outcomes experience paradoxical feelings of ... different regions of the brain, according to research ... at the Princeton Neuroscience Institute at Princeton University. ... the desirability of more than 300 products using ... of paired products with different or similar values ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 In ... Tuesday, President Obama cited the Atlanta BeltLine Workforce ... programs from across the country ( http://www.whitehouse.gov/ready-to-work ... an essential pillar of U.S. economic strategy and ... , “This recognition from President Obama highlights the ...
Breaking Medicine News(10 mins):Health News:GranuFlo Lawsuits Move Forward in Federal Court, With Issuance of Protective Order for HIPAA Information, Bernstein Liebhard LLP Reports 2Health News:GranuFlo Lawsuits Move Forward in Federal Court, With Issuance of Protective Order for HIPAA Information, Bernstein Liebhard LLP Reports 3Health News:GranuFlo Lawsuits Move Forward in Federal Court, With Issuance of Protective Order for HIPAA Information, Bernstein Liebhard LLP Reports 4Health News:Dr. Upadhyaya Joins CarePoint Health Medical Group 2Health News:Overweight and obese preschoolers lose more weight when parent is also treated 2Health News:Overweight and obese preschoolers lose more weight when parent is also treated 3Health News:Brain's dynamic duel underlies win-win choices 2Health News:Brain's dynamic duel underlies win-win choices 3Health News:President Cites Atlanta BeltLine Workforce Partnership in Healthcare as National Model 2Health News:President Cites Atlanta BeltLine Workforce Partnership in Healthcare as National Model 3Health News:President Cites Atlanta BeltLine Workforce Partnership in Healthcare as National Model 4Health News:President Cites Atlanta BeltLine Workforce Partnership in Healthcare as National Model 5
... pharmaceutical companies, The Global Alliance for TB Drug Development ... to coordinate the study to uncover the potential of ... treatment of tuberculosis (TB). ,Mycobacterium tuberculosis infects ... new cases of active TB and two million deaths ...
... are both of great public health importance in tropical ... acute malaria episodes are associated with transient increases of ... that malaria episodes might accelerate HIV-1 disease progression and ... the deleterious effects of HIV-1 infection on malaria. In ...
... issue of the Academy of General Dentistry's monthly newsmagazine, ... and is the most important factor in the prevention ... of the population. ,"Flossing every 24 hours to ... said Gordon Isbell, DMD, MAGD, spokesperson for the Academy ...
... deceptively simple sugar is in fact a critical regulator ... that, when disturbed, this process could contribute to cancer ... steps and timing of cell division, the researchers say. ... is used inside cells to modify proteins, turning the ...
... range of user-controlled products that would help women protect ... be developed in any form that is convenient to ... ,These microbicides will enable women to negotiate ... at risk and would also help avoid unwanted pregnancies, ...
... articular lipomatosis) is a rare, benign intra-articular lesion of ... tumour of the synovium, and forms part of the ... ,About 50 cases of Lipoma arborescens have ... reports of involvement of other joints including the hip, ...
Cached Medicine News:Health News:Historic trial for tuberculosis launched together by leading drug companies 2Health News:Malaria infection can accelerate HIV infection and disease progression 2Health News:Sugar Helps Control Cell Division 2Health News:Lipoma Arborescens: A Rare Tumor Of The Knee 2
... V is a low viscosity bone cement, ... vertebroplasty. The bone cement is injected into ... Osteopal V is used for the augmentation ... zirconium dioxide is included in the cement ...
Leadpoint Micro-Electrode Recording...
Based on the trusted Schaltenbrand-Wahren Atlas for Stereotaxy of the human brain, Atlasplan Software provides anatomical detail of the basal ganglia region of the brain and can help confirm target a...
Stereoplan, a three-dimensional software package for planning stereotactic procedures. Stereoplan provides diverse compatibility by supporting both the Radionics CRW frame and the Leksell G frame....
Medicine Products: